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Abstract
In the last half a century, researchers and scientists discovered the application of somatic cell nuclear transfer (SCNT) to clone 
mammalian embryos to produce a line of pluripotent stem cells for medical and laboratory use.  This is a breakthrough technology 
that is applied to stem cell research, regenerative medicine, and cloning.  Somatic cells are non-germ cells that are differentiated 
but provide the nuclei that are transferred to enucleated oocytes. The replacement of the nuclei results in a developing embryo 
that contains the genetic information of the donated nucleus, which can either be transplanted into a surrogate mother to 
produce a genetically similar offspring or grow in-vitro to extract embryonic stem cells (ESC). This process has made it possible 
for the cloning of numerous mammalian species, such as pigs, cattle, mice, and, recently, primates. Although success has been 
evident in mammals, human derivation of pluripotent embryonic stem cells has been difficult to obtain. The difficulty stems from 
the premature activation of the oocyte and the improper reprogramming of the donated nucleus. This paper focuses on the 
development of human nuclear transfer embryonic stem cells (ntESC) and its application in regenerative medicine.  Studies done 
on primates provide information on the barriers of this procedure on humans and the proper modifications on regular SCNT 
protocol. The use of deacetylase inhibitor TSA, phosphate inhibitor caffeine, and HVJ-E for proper membrane fusion are only some 
of the recent methods found for proper nuclear reprogramming and embryonic development. Breakthroughs in the methylation of 
DNA and histones in mice provided insight to a barrier in human embryo development.  As a result, derivation of embryonic stem 
cells was successful and tested for pluripotency.  Insulin beta cells and cardiomyocytes have been produced using this modified 
SCNT protocol and hold great potential for the future of science.  The use of nuclear transfer embryonic stem cells is important 
in the development of stem cells that can differentiate into specialized cells, such as neurons, that can potentially be used to cure 
disease, like Parkinson’s.  Even more so, these cells will retain the genome of the patient and reduce immune incompatibility. The 
paper goes on to discuss the ethical issues that impede researchers from advancing in this area.
Can Somatic Cell Nuclear Transfer Produce Human 
Pluripotent Stem Cells for Regenerative Medicine?
Alexandra Iskhakov
Alexandra Iskhakov graduated in January 2019 with a B.S. degree in Biology.
Introduction
Somatic cell nuclear transfer (SCNT) is a laboratory technique in 
which the somatic cell nucleus is transferred into an enucleated 
oocyte.  The egg is developed into a blastocyst, an early embry-
onic stage where the opening of a cavity in the morula between 
the inner cell mass and the enveloping layer is filled with fluid. 
This procedure was first theorized in 1938 by Hans Spemann, a 
German embryologist, in his book Embryonic Development and 
Induction.  He proposed an experiment to replace the nucleus 
of an unfertilized egg with a differentiated embryo nucleus. He 
pondered on whether such a transplant of a differentiated nu-
cleus can give rise to an organism (Wellner, 2010). This was a 
start to the idea of cloning that was initially attempted in 1952. 
Scientists Robert Briggs and Thomas King transplanted nuclei 
from an advanced blastula cell into enucleated eggs of Rana pipi-
ens, also known as leopard frogs. They saw a normal development 
of embryo resulting in the first cloned organism. Their study pro-
vided a basis for the SCNT protocol. As well, they determined 
that success is attributed to the transfer of a nucleus from the 
same species of frog. Transplanting the nucleus of a bullfrog led 
to an arrest at the blastula stage and inevitably died (Briggs et. 
al, 1952). Alluding to the core principle in SCNT mechanics of 
donor nucleus and oocyte recipient compatibility. 
In 1996, the first cloned mammal using a fully differentiated 
adult cell was executed by Campbell et al. (1996) in Scotland. 
Dolly, the cloned sheep born in 1997, was a breakthrough in 
determining the nuances of SCNT. They figured out that the 
development of embryos reconstructed by nuclear transfer is 
highly dependent on the interaction of the donor nucleus and 
recipient cytoplasm (Campbell et al., 1996). Their findings aided 
in further successes of cloned organisms and nuclear transfer 
embryonic stem cells (ntESC) derivation. Such findings include 
the effects of cytoplasmic kinase activity and maturation pro-
moting factor (MPF) on chromosomal damage. The expression 
of cytokeratin and lamin A/C, markers associated with differen-
tiation, was also reported indicating the development of ESC. 
Research in this area after this incident paved the road to de-
velop human ntESC and the extensive studies done on primates 
contributed to a modified SCNT approach. 
The important application of this process is to produce 
a culture of embryonic stem cells that are created from the 
inner cell mass of the blastocyst. Stem cells are undifferentiated 
cells that can either produce cells that continue as stem cells 
or are differentiated into specialized cells.  The implications of 
this procedure of generating personalized embryonic stem cells 
is useful for disease mechanism, and development of therapies 
(Tachibana et al, 2013), i.e. regenerative medicine or replacing 
damaged cells in patients, like cardiomyocytes to replace dam-
aged heart tissue or insulin-producing beta cells for diabetic 
patients, by eliminating the prospect of immune incompatibility 
(Lanza et al, 1999). However, therapeutic cloning refers to the 
derivation of nuclear transfer embryonic stem cells without 
uterine transplantation that has been successful in mice and 
cattle, derived from ntESC lines in cloned blastocysts (Yang et. 
al, 2007). However, human ntESC has been notoriously difficult 
due to its failure to progress past the eight-cell stage because of 
inactivation of critical embryonic genes. Due to ethical and legal 
restrictions, further research in this area is moving at a slower 
pace. Therefore the question arises, can SCNT be used to pro-




The information gathered in this paper was collected from sev-
eral sources such as Touro College Online Library and NCBI. 
The searches for “Somatic cell nuclear transfer”, “Cloning”, 
and “Therapeutic Cloning” led to the majority of articles used 
obtained from PubMed and Nature. The articles discuss the 
experimental studies done at various times and an analysis of 
these studies provided material for this discussion. Some review 
articles were necessary in the development of this analysis.
Discussion: Nuclear Reprogramming
For successful embryonic development the proper nuclear and 
cytoplast-mediated reprogramming is necessary. Campbell and 
colleagues (1993) specified morphological events that occur in 
nuclear transfer at the merging of a nucleated blastomere or 
karyoplast into the cytoplast of an enucleated metaphase II ar-
rested oocyte (MII).  Oocytes in MII state have a higher success 
rate in nuclear reprogramming in the cytoplasm due to certain 
factors. In mammals, the fusion of the two specimens is induced 
by an electric pulse to promote fusion and activation of the 
enucleated egg. Studies in mice, pigs, and cattle display that cer-
tain morphological events occur at the point of fusion, including 
nuclear envelop breakdown (NEBD) followed by premature 
chromosome condensation (PCC), dispersal of nucleoli, refor-
mation of the nuclear envelope, and nuclear swelling (Campbell 
et. al, 1993). The induction of NEBD and PCC are important for 
the reprogramming of gene expression and increased embryo 
development. These events vary depending on both the species 
and nuclei at different cycle stages. In rabbits, blastocyst devel-
opment was found to be greater when the blastomeres were 
in G1 or early S phase than in late S phase or G2 (Collas et. al, 
1992). A possible explanation for such observations was found 
in the cell cycle regulation with an emphasis on cellular DNA 
replication by maturation promoting factor (MPF). 
A study showed the necessary implication of MPF activity at 
G1/S and G2 stages. MPF is a complex of two proteins, cyclins 
and p34cdc2. P34cdc2 is a protein kinase that is regulated by 
phosphorylation changes and interaction with cyclins. P34cdc2 
does not change during the cell division cycle while cyclin does. 
P34cdc2 kinase triggers the entry of the cell into the M phase 
that produces NEBD, chromatin condensation, and other mor-
phological changes in the cell. Therefore, MPF primary func-
tion is to promote nuclear breakdown, spindle formation, and 
chromatin condensation. Mammalian oocytes at the MII phase 
contain high levels of MPF. Upon fertilization or activation, MPF 
levels decline resulting in the decondensation of chromatin and 
formation of pronuclei. Therefore, NEBD and PCC occurrence 
in the donor nucleus suggests a correlation between MPF with 
NEBD and PCC activity. NEBD and PCC probably remove 
the nuclear membrane to allow ooplasmic remodeling factors 
access to the donor cell chromatin for the re-replication of 
previously replicated DNA and the synthesis of DNA in the 
donor nucleus at any cell stage. As well as, contributes to the 
reformation of the nuclear membrane. A problem arises when 
MPF activity is low at the time of fusion (Campbell et al., 1993).
When MPF is low at the time of fusion, from premature ac-
tivation of the enucleated egg, the nuclear membrane is main-
tained. G1 donor nuclei will replicate their DNA, however, G2 
nuclei will not rereplicate and a low frequency of development 
arises. However, interestingly enough, this suggests that, at slow 
MPF decline at the time of fusion, in any other phase other than 
G1, the DNA will rereplicate resulting in aneuploidy. This cor-
relates with the results of the study done by Collas et. al (1992) 
regarding the development of rabbit blastocyst. In rabbits, at G1, 
early S, and late S phases, metaphase plates, and spindles were 
detected but abnormalities, like incomplete spindle formation 
and incomplete chromosome condensation, was present in late 
S phases (Campbell et. al, 1993).
A study was done by Mitalipov et. al (2007) built on the aspect 
of MPF regulation in primates and nuclear remodeling through 
lamin A/C staining. Lamins, an intermediate filament super-
family of proteins, are part of the nuclear lamina found on the 
inner layer of the nuclear envelope. Lamin types A and C are 
expressed in many differentiated somatic cells. Lamins A/C are 
essential in size, shape, and strength determination of the nucle-
ar envelop as well as maintaining lamina structure. (Hutchison 
and Worman, 2004). These proteins tend to depolymerize 
during late prophase and become undetectable in the MI or MII 
oocytes. At fertilization, cytoplasmic lamins are gathered into 
the forming pronucleus (Prather et al., 1989). Lamin A/C has 
been used to assess the extent of nuclear remodeling following 
SCNT because of the changes in the nuclear lamina, as shown in 
this 1study, in monkeys.
MPF levels, as mentioned before, result from premature oo-
cyte activation and a failure to induce nuclear remodeling. In 
studies with mice and cattle, the fusion of a donor cell with an 
oocyte was done through electroporation. Electroporation in 
a calcium ion fusion medium increases the calcium levels that 
trigger a rapid decline of histone H1 kinase and even MPF activ-
ity. Using electrofusion with calcium ion or magnesium ion free 
buffers or performing all manipulations free of these ions can 
minimize premature activation of the oocyte (Mitalipov, 2007). 
An improvement in the in-vitro development of pig (Boquest et 
al., 2002) and primate blastocysts (Mitalipov et al., 2007), which 
was shown from lamin A/C profile under these modifications was 
similar to those detected in sperm-fertilized controls. To supple-
ment electroporation as a fusing agent in human SCNT, HVJ-E 
virus, hemagglutinating virus of Japan-envelope, a non-infectious 
vesicle used as an agent for cell fusion, showed a high rate of 
fusion. However, embryonic development past the compact mor-
ula failed, even though ionomycin and 6-Dimethylaminopyridine 
(DMAP) were used to activate the cell at the appropriate time. 
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Therefore, implementing electroporation, which is not necessary 
for cell fusion but rather for timely cell activation, increased blas-
tocyst development.  It is necessary as an activation stimulus in 
conjunction with ionomycin and DMAP (Tachibana et. al, 2013). 
Extended exposure of the chromatin to the non-activated MII 
cytoplast enhances embryonic development. An MII oocyte has 
high levels of MPF but enucleation, which also removes cyto-
plasm from the oocyte, reduces MPF levels (Lee & Campbell, 
2006). The disassembly of the nuclear lamina with the chro-
mosome condensation is attributed to the phosphorylation of 
MPF. To prolong the presence of MPF, use of caffeine, a pro-
tein phosphatase inhibitor, or MG-132, a proteasome inhibitor, 
increased nuclear remodeling in the donor nucleus. MG-132 
prevents spontaneous oocyte activation, as seen by the weak/
partial lamin A/C signal in C/C1 (figure 1). More exposure to 
MG-132 reduces the lamin A/C signal and increases the chro-
matin condensation, as seen by DAPI blue stain (Mitalipov et. 
al, 2007). However, proteasome activity impacts development 
events, in contrast to caffeine that has high cleavage rates and 
regular blastocyst formation. However, caffeine does not affect 
the frequency of blastocyst formation (Lee & Campbell, 2006; 
Mitalipov et. al, 2007). Embryos usually do not develop past day-
12. These conclusions suggest there is more than merely nuclear 
remodeling that affects the success of SCNT. 
Premature activation of the MII oocyte is a likely occurrence, 
especially in aged or overstimulated oocytes. Therapeutic clon-
ing or ESC derivation from discarded, aged, or failure-to-fertilize 
oocytes are unlikely to succeed (Mitalipov et al., 2007). Ovarian 
stimulation can also affect the quality of the oocyte, thus, tamper-
ing with the success of the procedure. A study was conducted to 
compare three groups of oocyte donation cycles, <10 oocytes 
per cycle, 11-15 oocytes per cycle, and >16 oocytes per cycle. 
Survival of the egg after spindle removal until embryonic cleavage 
was similar amongst the three groups. However, more >16 oo-
cyte/cycle groups arrested after the eighth cell stage. Additionally, 
the quality of the blastocysts correlated inversely with the num-
ber of oocytes collected per cycle. ntESC derived from these 
oocytes were mainly from the <10 oocyte/cycle group and none 
from the >16 oocyte/cycle group (Tachibana et al., 2013). This 
shows that both the donated nucleus and recipient oocyte con-
tribute to the success of ntESC derivation and development. 
Another challenge to SCNT embryonic development is the 
consequence of microtubule and centrosomal protein depletion. 
This is a result of enucleation of the oocyte that extracts the 
spindle with defective reformation of the spindle by the donor 
nucleus. However, when the somatic cell nucleus is transferred 
to an oocyte containing its own chromosomes it results in a 
functional polyploid blastocyst that can develop into ESC. This 
can mean that certain reprogramming factors, associated with 
the spindle apparatus, are present in the MII oocyte (Tachibana 
et al., 2013) and are removed upon enucleation.  Modification in 
the SCNT protocol of spindle removal is necessary to success-
fully execute nuclear reprogramming and blastocyst formation. 
The standard procedure of enucleation and spindle extraction 
is by adding bisbenzimide staining and UV exposure in mammals, 
such was executed in pigs (Polejaeva et al., 2000). However, if 
meiosis-specific factors are retained during spindle removal 
then only spontaneous activation of the cell causes its decline. 
By using the methods above to protect against premature ac-
tivation, SCNT embryo development increases and spindle-like 
structures are formed. This method increased ESC derivation 
in primates that displayed similarities to human IVF-derived 
blastocysts than the manipulated spindle transfer embryos 
(Tachibana et al., 2013). 
Epigenetic Regulation
Nuclear reprogramming is a crucial step for the success of 
embryonic development. However, it is not limited to the first 
steps of activation. Reprogramming gene expression in the inner 
cell mass (ICM) is a necessary component for the continua-
tion of embryonic development and especially for derivation of 
pluripotent ntESCs. Normal development requires epigenetic 
modifications, which includes DNA methylation and histone 
modification. The ICM and trophectoderm are distinguished in 
the blastocyst with a predominant increase of DNA and histone 
Figure 1: Lamin A/C signaling and DAPI staining for exposure of 




methylation in the ICM, affecting genomic imprinting and X 
chromosome activation in females (Yang et al., 2007). 
In normal embryonic development, methylation occurs prefer-
entially in the ICM, a process in which a methyl group is added 
to the 5th carbon of the cytosine ring next to a guanine base, 
through DNA methyltransferases (DNMT). In female mice, for 
example, demethylation occurs due to DNMT during subsequent 
cleavages. In male mice, it is demethylated in the pronucleus after 
fertilization.  Chromatin configuration establishes the ‘histone 
code,’ a cellular memory responsible for maintaining the identity 
of differentiated cells. Histones are proteins that contribute to 
the make-up of chromatin.  They have an exposed N-terminus 
end, which is either modified through methylation, acetylation, 
ubiquitinylation, or phosphorylation. For example, the acetylation 
of histone 3 Lys9 (H3K9) induces an open chromatin configura-
tion giving transcription factors access while the methylation or 
demethylation of H3K9 inactivates it (Yang et al., 2007). 
Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, 
has shown a significant impact on embryonic development in 
mammals and primates (Sawai et al., 2012; Mitalipov et al., 2007). 
A study was conducted on bovine animals using 5nM and 50nM 
of TSA. The group that was treated with 50nM of TSA showed 
significant blastocyst development. TSA increased histone H4K8 
and histone H3K9K14 acetylation, which activates gene tran-
scripts. However, FGF4 in bovine, required for ICM formation 
and trophectoderm differentiation, was still considerably low 
and did not change through the treatment of TSA. It is mainly 
affected by DNA methylation signifying that DNA methylation 
is an important factor for nuclear reprogramming (Sawai et al., 
2012). Therefore, it is proper to conclude that TSA is necessary, 
as Mitalipov’s study on primates and Tachibana’s study on human 
ntESC both come to the same conclusion, yet DNA methylation 
is another component to embryonic development. 
DNA and histone methylation is pertinent to improve the 
ntESC derivation. The first developmental defects of SCNT ap-
pears at the time of zygotic genome activation (ZGA) which 
occurs at the 4 to 8 cell stage in humans and bovine and at the 
2-cell stage in mice. Difficulties in ZGA are due to epigenetic 
barriers existing in the genome. Certain genomic domains re-
sistant to ZGA in SCNT embryos, known as reprogramming 
resistant regions (RRRs), have been identified.  Enrichment of 
mouse RRRs with histone H3, lysine 9 methylation (H3K9me3) 
in the donor genome results in a barrier to transcriptional re-
programming. They must be removed by specific demethylase 
or by ridding it of H3K9 methyltransferases. Kdm4d, H3K9me3-
specific histone demethylase, greatly reduces H3K9me3 levels. 
The injection of Kdm4d mRNA increased the blastocyst rate up 
to 88.6% (Matoba et al., 2014). 
In the study done by Chung et al. (2015), it was found that 
H3K9me3 also serves as a barrier in human SCNT. Using the 
same oocytes that failed to develop into blastocysts, they demon-
strated that Kdm4a overexpression significantly improved em-
bryonic development. Compared to the IVF derived embryos, 
of 707 genomic regions in SCNT embryos, 308 were termed as 
RRRs with the same enrichment of H3K9me3 as seen in mice. 
This study also showed that the injection of Kdm4a wild-type, 
not Kdm4d catalytic mutant used in the original study on mice, 
had a greater blastocyst rate, 90.3%, in SCNT embryos. To test 
the efficiency in this demethylase on humans, Kdm4a mRNA 
was injected at different stages of SCNT embryonic develop-
ment. Injecting it upon activation, after fusion by HVJ-E, showed 
no effect prior to ZGA completion. However, the effect was 
noticeable at the end when 8 blastocysts were developed, with 
no development of the control group. In a conventional ESC 
derivation medium, seven attached to the MEF feeder cell and 
four stable ntESC lines were derived. As shown in Figure 5, im-
munostaining revealed that NANOG, OCT4, SOX2, SSEA-4, and 
TRA1-60, transcription factors that maintain ESC differentiation, 
were all expressed similar to human ESC line derived by IVF. 
Likewise, these ntESC’s expressed pluripotency marker genes 
that were indistinguishable from IVF derived ESC. Additionally, 
these ntESCs underwent immunostaining of embryoid bodies 
(EB), aggregates of ESC, for two weeks in vitro giving rise to the 
Figure 3: TSA structure. Selleckchem.com
Figure 4 (Chung et al., 2015)
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differentiation into all three germ layers. Proving its differenti-
ation ability. Karyotyping, the process of chromosome pairing, 
demonstrated normal chromosomal number and the same sex 
chromosome of the donor nucleus, and Short Tandem Repeat 
(STR) analysis showed all 16 repeat markers on the genome is 
perfectly matched to the donor somatic cell. A sequence analy-
sis of mitochondrial DNA (mtDNA) demonstrated that the sin-
gle-nucleotide polymorphism of ntESCs matched the mtDNA 
of the donor oocyte and not the donor nucleus. A necessary 
analysis that demonstrates the idea that mtDNA is transmitted 
by the fertilized oocyte and not from the DNA in the cell’s 
nucleus (Chung et al., 2015).
Although blastocyst development in SCNT embryos was im-
proved, the success of humans, merely 27%, compared to the suc-
cess of mice, 90%, suggests that all modifications to SCNT protocol 
must be utilized, especially proper oocyte quality. That is a major 
factor for ntESC derivation. Human oocyte varies tremendously 
even from a single ovulation. Therefore, even some blastocysts 
formed through IVF were not supported (Chung et al., 2015). 
Fetal vs. Adult Somatic Cell
In order for SCNT to be regarded as having practical medical 
significance there must be a way to generate ntESC from adult 
somatic cells. Most experiments use various fetal fibroblasts as 
somatic nuclei donors. However, patients that are in need of this 
procedure are mainly aged. Therefore, a recent study done by 
Chung et al. (2014) determined whether dermal fibroblasts from 
35 and 75- year-old males can undergo successful SCNT proce-
dure. The debate on adult vs. fetal cells is regarding the age-re-
lated changes, such as shortened telomeres and oxidative DNA 
damage that can potentially obstruct nuclear reprogramming. 
Even though fetal fibroblasts were used in numerous researches, 
there were no clear claims of age impedance on SCNT. Using 
the non-modified, standard SCNT protocol, no aneuploidy was 
produced in the resultant human ESC. Therefore, the modi-
fied SCNT protocol established by Mitalipov et al. (2007) and 
Tachibana et al. (2013) on fetal fibroblasts was used, with two 
groups forming. One group was activated 2 hr after implantation 
and the other group was activated after 30 min. However, only 
two blastocysts hatched from the 2 hr group, one from each age 
subtype, leading to the generation of ESC lines. The difference 
in time duration can be explained by the possibility for the nec-
essary extra time needed for reprogramming that is dependent 
on the exposure of the donor nucleus to the recipient oocyte 
cytoplast. Both ntESC lines displayed the same sixteen STR 
markers located on the human autosomal and allosomal loci as 
the donor somatic cell and differed from the oocyte donor. The 
mtDNA was verified being inherited by the oocyte donor in 
both ntESC lines and expression of transcription factors OCT-4, 
SSEA-4, TRA-1-60, and TRA-1-81 was present. Pluripotency was 
confirmed through spontaneous differentiation into the three 
germ layers by immunostaining of embryoid bodies. Further 
confirmation of pluripotency was through teratoma formation 
assays that demonstrated outgrowth of tissue from the germ 
layers.  Despite the low success rate, this study portrayed the 
efficiency of the modified SCNT protocol and greatly implies 
the possibility of using SCNT to generate patient-specific ESC 
for medical use (Chung et al., 2014).
Application of Therapeutic Cloning on 
Regenerative Medicine
Therapeutic cloning holds great promise in regenerative medi-
cine and gene therapy. It has numerous research and clinical ap-
plications, such as producing a vector for gene delivery, creating 
animal models of human diseases, and cell replacement therapy 
in regenerative medicine. It can permanently cure Parkinson’s 
disease or diabetes mellitus. Barberi et al. (2003) conducted 
a study on mice using SCNT with nuclei from cumulus and 
tail-tip cells. Two ntESC lines were differentiated into motor, 
GABAminergic, serotonergic, and dopaminergic neurons, that 
displayed synapse formation and normal electrophysiological 
properties in vitro. Mice with Parkinson-like lesion were in-
jected with dopaminergic neurons into the cortical striatum 
induced by 6-hydroxydopamine. An 80% survival rate 8 weeks 
post-transplantation was observed from ntESC contrary to 40% 
for stem-cell derived neurons (Kfoury, 2007). 
Furthermore, SCNT can allow for organogenesis and pa-
tient-specific rescue of genetic mutations. In cell replacement 
therapy, therapeutic cloning has the potential to create various 
types of tissues such as osteoblasts to counteract osteoporo-
sis. Deshpande et al. (2006) transferred motor neurons derived 
from ESC to rats with a severed spinal cord showing SCNT 
application for spinal cord regeneration. A potential cure for 
paralysis in humans.  Therapeutic cloning eliminates the issue of 
immune rejection and organ shortage by engineering tissues and 
organs. Patient-specific cardiomyocytes, blood vessels, and skin 
can treat infarctus, atherosclerosis, and severe burns (Kfoury, 
2007). With the use of the modified SCNT protocols, diploid 
pluripotent stem cells that were derived from a patient with 
type 1 diabetes were produced (Yamada et al, 2014). Such ad-
vancements in medicine hold hope for cures of various diseases. 
iPSC vs. ntESC
IPSCs, induced pluripotent stem cells, is a laboratory tech-
nique that reprograms differentiated cells back to pluripotency 
using specific transcriptional factors. The medical application of 
human iPSCs has opened the door for rapid stem cell therapy. A 
set of essential transcription factors, called reprogramming fac-
tors, trigger the destruction of the existing state of somatic cells 
by changing their epigenetic status, leading to alterations in their 
gene expression. The changes in the gene expression induce 
secondary epigenetic changes, including DNA methylation and 
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alterations of the nuclear structure. However, there are road-
blocks to reprogramming that need to be removed because cel-
lular identity is stabilized. However, transcription factors such 
as Oct4, Sox2, Klf4, and c‐Myc are sufficient to destabilize the 
existing order in the original cells and re-construct a new order. 
Therefore, transcription factors associated with development 
may undertake important actions during the reprogramming 
process. This produces stem cells that are similar to embryonic 
stem cells but has a few disadvantages when compared to ntE-
SCs (Takahashi & Yamanaka, 2013). 
ESC is considered the ground state which is believed to have 
a greater chance of successful differentiation than iPSC. During 
reprogramming, iPSCs-specific methylation and transcriptional 
abnormalities in imprinted regions and X chromosomes were 
observed with such abnormalities less frequent in ntESCs 
(Nazor et al.,2012). In some instances, a number of highly pro-
liferative colonies appear that are not pluripotent and can form 
into tumors. Furthermore, iPSCs do not efficiently silence the 
expression pattern from where they are derived from and fail 
to induce some ESC specific genes (Bilic & Belmonte, 2011). 
A major advantage of SCNT-based ntESCs is the fact that 
it contains mtDNA originating from the oocyte.  Irrespective 
of the nuclear donor cell mtDNA, ntESCs have the potential 
to produce functional cells and tissues for cell therapies. Thus, 
SCNT offers a strategy for correcting mtDNA mutations and 
retaining the metabolic function of pluripotent cells from pa-
tients with inherited mtDNA diseases.
 MtDNA that is specific to the oocyte recipient of cloned 
embryos was first determined in the study done by Evans et 
al. (1999), with co-researcher Dr. John Loike. They showed nu-
clear transfer-derived sheep were homoplasmic. The random 
partitioning of mtDNAs does not occur. This may be due to 
the failure of the donor mitochondria to enter the ooplasm 
following electrofusion. It can be hypothesized that an active 
mechanism operates to destroy the donor mitochondria in the 
recipient ooplasm, similarly to what is thought to happen to 
sperm-derived mitochondria in fertilized ova in human repro-
duction. These results have implications for future attempts to 
correct maternally inherited mitochondrial genetic disorders 
by nuclear transfer involving a somatic or germline cell from a 
woman containing a pathogenic mtDNA mutation but normal 
nuclear DNA and a recipient enucleated oocyte. 
Ethical and Legal Issues
Research in this field has been held back due to controversial 
ethical issues. Legal constraints and lack of funding results in 
the impediment of therapeutic cloning (Lo & Parham, 2009). A 
major objection to SCNT is the belief that creating embryos 
for research, with the intention of mutilating these embryos, 
violates human respect and integrity. Sandel (2004) argued in his 
article on embryo ethics, “Although every oak tree was once 
an acorn, it does not follow that acorns are oak trees, or that 
I should treat the loss of an acorn . . . as the same kind of loss 
as the death of an oak tree.” This is an opinion based question 
whether an embryo varies in essence from a developed human 
being. Evaluation whether the use of embryos for medical re-
search justifies its destruction. Meanwhile, legislative actions, es-
pecially in Europe, hinders SCNT advancement that contributes 
to its slow progression.
Conclusion
Therapeutic cloning is feasible through modified SCNT proto-
col. Research in mammals and primates aided in the success 
of human ntESC derivation by establishing the correlation be-
tween oocyte and donor nucleus quality, nuclear reprogram-
ming, and proper gene expression. All steps led to the deriva-
tion of pluripotent ESC that were differentiated into various 
specialized cells, such as cardiomyocytes and insulin beta cells. 
The developed embryo harboring mtDNA from the recipient 
oocyte holds an advantage over iPSC cells by constituting met-
abolically functional cells from mitochondrial diseased cells. 
More research is needed to expand and apply this technique in 
medical practice; however, ethical and legislative actions repress 
the advancement in this area.
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